Lumateperone in Bipolar Depression
The Carlat Psychiatry Report, Volume 20, Number 2, February 2022
John C. Raiss, MD.
Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.